Startup India · DPIIT Recognized · Healthcare & Life Sciences
ADG Catalyst —
Building India's Future in AI-Driven Healthcare
AI SaaS · Digital Twin Precision Drug Delivery · NeuroMorphic Chip Computing.
Transforming diagnostics and therapeutics for a billion lives.
850
TOPS Performance
5.4×
Better than CycleGAN
₹500Cr+
Addressable Market
14×
Projected ROI
Our Core Innovations
🧠
AI SaaS · I-Translation
QuadGAN-XAI powered medical image translation. CT↔MRI synthesis at ₹500/scan vs ₹8,000 traditional MRI. FID score 20 — 5.4× better than CycleGAN.
Patent: 202611033808 · Amended Examination Stage — Rebuttal Submitted · One Step from Grant
💊
Digital Twin Drug Delivery
Marco Polo model — NanoRL-DT reinforcement learning for closed-loop precision oncology. 99.2% tumour reduction, 98.1% time-in-range, zero safety violations.
Patent: 202611100254 · Examination Stage
⚡
AIM HyperFusion™ Chip
4-layer neuromorphic chip — CMOS/SIMD, RRAM PIM, HBM3, Photonic NoC. 127 TOPS/W efficiency. 0.021 pJ/MAC. 4 TB/s bandwidth.
Patent: 202611089629 · Filed, Grant Pending
Government Recognized · DPIIT Startup India
Recognition No.DIPP264655
Issued30 May 2026
Valid Until20 May 2036
SectorHealthcare & Life Sciences / Healthcare Technology
MSMEUDYAM-HR-05-0168553
GST07ABFCA7510A1Z8
26+
Years Experience
13+
Awards Won
$35M
Revenue Target 2031
Q1 2029
Break-Even
ADG CATALYST OPC PRIVATE LIMITED · New Delhi, India